Evolus has filed a material event with the SEC regarding Jeuveau (prabotulinumtoxinA-xvfs, formerly Newtox) and its Evolus Rewards loyalty program, signaling an aggressive push to capture medspa market share. The company's strategy centers on rebate-based incentives and volume commitments—a direct challenge to AbbVie Allergan's dominant Allē program and Galderma's Aspire platform.